using montelukast as an add-on treatment in nephrotic syndrome of pediatrics: a randomized clinical trial study

Background: montelukast, as a non-steroidal anti-inflammatory drug, could reduce inflammation in nephrotic syndrome (ns). this study aimed to evaluate the therapeutic effect of montelukast as adjunctive agent in pediatric ns. methods: this clinical trial study was conducted on patients with ns. the patients were assigned into two equal groups (n = 25 in each) of intervention (steroid + montelukast) and control and treated for one month. one month later, in the follow-up stage, their proteinuria was measured. the results before and after treatment were statistically analyzed by spss software version 21, and the final report of the project was presented. results: the age of participants in the intervention and control groups was 7.26 ± 4.23 and 6.79 ± 3.91 years, respectively (p = 0.68), and there were 10 female participants in both groups (p = 1.0). albumin levels in 96% of the control group and 76% of the intervention group were 1.5 - 2.5 µg/dl (p = 0.037). also, 48% of participants in the control group were corticosteroid dependent, and 60% of participants in the intervention group responded to corticosteroids (p = 0.194). the severity of nephrotic syndrome was moderate in 60% of participants in the control group and mild in 60% of participants in the intervention group (p = 0.138). conclusions: the results of present study showed that recovery rate was higher in the intervention group, but the difference was not statistically significant.